SOD1-G93A transgenic Mouse Model

SOD1-G93A high copy number mice express human SOD1 with the G93A mutation under control of the cistronic human SOD1 promotor. Mutations in this gene have been linked to familial Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease). The SOD1-G93A mice show a phenotype similar to Amyotrophic Lateral Sclerosis in humans. They develop paralysis in one or more limbs within a few weeks of age.
These mice are a valuable tool to study the influence of new drugs on neuromuscular disorders such as Amyotrophic Lateral Sclerosis.

Figure 1: Longitudinal grip strength measurement of SOD1 mice, lipid peroxidase in the lumbal and thoracal spinal cord and astrocytosis in the ventral thalamus of 18-20 week old SOD1 mice. A: Force that animals can use to grip the handle in grams. Two-way ANOVA with Bonferroni’s post hoc test. Mean ± SEM; B: TBARS assay, mean + SEM; Two-way ANOVA with Bonferroni’s post hoc test. C: Quantitative analysis of astrocytosis (GFAP) in the ventral thalamus. IR: Immunoreactive area; Mean + SEM; t-test; *p<0.05; **p<0.01; ***p<0.001.

SOD1-G93A low copy number transgenic Mouse Model
QPS Neuropharmacology also offers research services with the SOD1 low copy number mouse model. Animals develop the same phenotype as the above described SOD1 high copy number mouse model, but disease onset is at about 6-7 months and thus extending the treatment window. Animals survive appr. 6 weeks after symptom onset.

QPS Neuropharmacology offers custom tailored study design for this model and we are flexible to accommodate to your special interest. We are also happy to advice you and propose study designs. QPS Neuropharmacology maintains its own colony directly in our research facility. Non-transgenic littermates are available as control animals needed for proper study design.

We would be happy to test your compounds in this mouse model! The most common readouts are:

Looking for something else? Please contact us!

You might be also interested in these related models

We are happy to receive your inquiry.

Facebook
Twitter
LinkedIn